A distilled field-record · a two-peptide blend
BPC-157 TB-500 is the Wolverine research blend, two peptides set down with their access status first.
Two distinct peptides mounted as two specimens — a 15-residue body-protection compound beside a 7-residue actin-binding fragment. This is what the published record on each establishes, with its regulatory and compounded-access status read first.
What the Wolverine blend is, set down plainly
BPC-157 TB-500 is a two-peptide pairing the research community calls the "Wolverine" blend, discussed as a tissue-repair stack. It is two synthetic peptides mounted side by side — not a single molecule, not an approved medicine, and not a co-formulation with a validated composition. Each specimen carries its own paper trail, and the most consequential facts about the pairing are regulatory, which is why this site sets the Wolverine legal status and 503A category before anything else.
The first specimen is BPC-157 — Body Protection Compound 157 — a 15-amino-acid pentadecapeptide (sequence GEPPPGKPADDAGLV, molecular weight roughly 1,419.5 Da) derived from a partial sequence of a protein found in human gastric juice [1]. The second is TB-500, a synthetic N-acetylated heptapeptide (Ac-LKKTETQ, roughly 889.0 Da) corresponding to residues 17-23 — the actin-binding region — of the 43-residue protein Thymosin Beta-4 [8].
That second provenance carries a caveat worth pinning to the page early. The "TB-500" sold and stacked is the seven-residue fragment, but the overwhelming majority of efficacy data attributed to it were generated with full-length Thymosin Beta-4 (~4,963 Da), not the 7-mer [4]. The blend inherits that gap: it leans on full-protein data for one of its two legs. Everything that follows is a digest of the published record — a labeled specimen plate, not a protocol, not a recommendation, and not a claim about the combination the literature has not made.
BPC-157 and TB-500: What the Wolverine Blend Pairs
BPC-157 and TB-500 are paired because they are described as acting through complementary but largely non-overlapping pathways — which is both the basis of the "synergy" claim and its limit [4].
BPC-157 supplies the cytoprotective, pro-angiogenic leg. In preclinical models it up-regulates VEGFR2 and promotes its internalization, driving the VEGFR2-Akt-eNOS pathway and modulating the nitric-oxide system [2]. In a fully transected rat Achilles tendon it improved load-to-failure, collagen organization, and tendon integrity versus untreated controls, dosed at 10 µg/kg or 10 ng/kg intraperitoneally [1].
TB-500 supplies the cytoskeletal leg. Its LKKTETQ motif binds monomeric G-actin in a 1:1 complex, regulating the actin dynamics that drive cell migration [3]. Thymosin Beta-4 — the parent protein — binds actin, mobilizes cells, decreases myofibroblast number, limits inflammation after injury, and promotes angiogenesis [4].
The details sit on the research page; the pharmacokinetic record, including BPC-157 and TB-500 half-life, sits on its own plate. The honest center of the pairing is what is missing: no controlled study has defined a combined dose, ratio, or endpoint for the two given together [9].
What Is the Wolverine Peptide Blend?
A research-community name for a two-peptide pairing of BPC-157 and TB-500, discussed as a tissue-repair "stack." It is not a single chemical entity, has no CAS number or molecular weight of its own, and is not an approved product. Commercial vials carry a combined per-vial mass — for example, 10 mg + 10 mg — but no standardized ratio is clinically validated [4].
What Are BPC-157 and TB-500?
BPC-157 is a synthetic 15-amino-acid pentadecapeptide derived from a human gastric-juice protein — the cytoprotective and angiogenic component [1]. TB-500 is a synthetic N-acetylated heptapeptide (Ac-LKKTETQ) from the actin-binding region of Thymosin Beta-4 — the cytoskeletal, cell-migration component [3][8]. The blend pairs the two as a tissue-repair stack.
What the record studies the blend for
In animal models, the two constituents have been studied separately for tendon, ligament, muscle, and wound repair and for angiogenesis [1][2][4]. BPC-157 carries the most-cited tissue-repair result — accelerated healing of a transected rat Achilles tendon [1] — and the clearest mechanistic arm, VEGFR2-driven angiogenesis [2]. TB-500's parent protein carries a settled actin-binding structure and a consolidated regenerative profile [3][4]. That distinction — strong single-compound animal work on one side, an unstudied pairing on the other — runs through every page here.
What Is the BPC-157 and TB-500 Blend Studied For?
In animal models, the two constituents have been studied separately for tendon, ligament, muscle, and wound repair and for angiogenesis [1][2][4]. The blend itself has no controlled human efficacy data; combined use is investigational. The reported uses are single-compound and preclinical, and for most of the "TB-500" data are drawn from full-length thymosin beta-4 rather than the marketed 7-mer [4].
What Is the Difference Between BPC-157 and TB-500?
They are two different peptides with two different jobs. BPC-157 is a 15-residue pentadecapeptide from a gastric-juice protein, acting as a cytoprotective and angiogenic signal through VEGFR2-Akt-eNOS [1][2]. TB-500 is a 7-residue acetylated fragment of Thymosin Beta-4, acting as a cytoskeletal actin-sequestration signal [3]. They are structurally unrelated, with distinct mechanisms; one signals vessels and tissue protection, the other the cytoskeleton [4].
The BPC-157 TB-500 Stack: Why the Research Community Pairs Them
The BPC-157 TB-500 stack is built on mechanistic complementarity. The pairing rationale is that BPC-157 supplies a local cytoprotective and pro-angiogenic signal while TB-500 supplies a cytoskeletal cell-migration signal, on the theory that two repair levers add up to more than either alone [4].
The honest framing matters. This is a theoretical extrapolation from each peptide's independently characterized mechanism — not a finding from a controlled combination study. A 2025 systematic review of BPC-157 in orthopaedic sports medicine, covering 36 studies with only one human among them, makes no mention of TB-500 or any combination [9]. The marketing language around "Wolverine" — rapid healing of any injury, performance enhancement — outruns a published evidence base that is preclinical, single-compound, and largely from animal models [11].
Because the blend has no validated quantitative profile of its own, the numbers on this site are constituent-level and labeled as such. Read each against its source through the frequently asked questions, and weigh the access status as the first fact, not the last.